Skip to main content
Premium Trial:

Request an Annual Quote

B. Braun Takes 20 Percent Stake in German Diagnostics Firm CeGaT

Premium

CeGaT, the Center for Genomics and Transcriptomics, said this week that healthcare product and service provider B. Braun Melsungen has taken a 20 percent stake in the firm.

The investment will allow CeGaT, based in Tübingen, Germany, to further expand its range of diagnostic panels and to distribute them internationally. CeGaT did not reveal the size of the investment.

According to its website, CeGaT currently offers 55 sequencing-based diagnostic panels for a range of genetic diseases, including ALS, FTD, dementia, Parkinson's disease, dystonia, neurokanthocytosis, epilepsy and metabolic disorders, hereditary eye diseases, neuromuscular diseases, and hereditary hearing loss (IS 10/26/2010).

The company, founded in 2009, is equipped with SOLiD 5500xl and SOLiD 4 instruments, an Ion Torrent PGM, and a capillary sequencer.

This is B. Braun's first entry into the genetic diagnostic market. "With CeGaT, we are taking a stake in a young, dynamic company that is perfectly aligned for the diagnostics market, one of the large growth markets of the future," said Heinz-Walter Große, chairman of B. Braun's board, in a statement.

B. Braun, based in Melsungen, Germany, provides products and services for anesthesia, intensive medicine, cardiology, extracorporeal blood treatment, and surgery. The company has more than 43,000 employees in more than 50 countries and reported €4.4 billion ($5.8 billion) in revenues in 2010.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.